Project Grant R01CA305375
- The National Cancer Institute (NCI) awarded a $487,393 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY, effective December 1, 2024 through November 30, 2029. The grant supports research to determine the role of RAD52, HELQ, and POLQ proteins in backup DNA double-strand break repair pathways, which are critical for the survival of homologous recombination deficient (HRD) cancer cells. The research aims to...
- This $238,722 federal Project Grant awarded on August 18, 2025 by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Sloan-Kettering Institute for Cancer Research supports research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The research aims to define the specific mechanisms that promote mutagenic DNA repair and drive acquired drug resistance in persister cancer cells, focusing on the role of the microhomology-mediated end...
- This Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports fundamental scientific research to study the mechanisms of how homologous recombination maintains genomic stability and induces genome rearrangements. The $305,927 award, effective September 1, 2025, will enable researchers at the University of California, Davis to advance their work on understanding the processing of...
- The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), awarded a $445,000 project grant to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant, awarded on January 22, 2025, supports DFCI's research on the molecular mechanisms of DNA double-strand break repair by homologous recombination, a critical process for cell survival and cancer prevention. The project aims to define the complex...
- The federal Project Grant award, titled "Homologous Recombination Repair Pathway Mutations and Genetic Mechanisms Shaping Anti-Tumor Immunity and Immunotherapy Efficacy," is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) in the amount of $713,601.00. The grant was awarded on August 1, 2025 and is scheduled for completion on July 31, 2030. The project aims to elucidate the mechanisms by which defects in the homologous recombination (HR) DNA repair...
- This federal Project Grant award of $390,000.00 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to elucidate the mechanisms underlying DNA double-strand break repair at Thomas Jefferson University, doing business as Sidney Kimmel Medical College. The research aims to determine the regulatory mechanisms of the multi-protein and multi-step process required to coordinate the repair of DNA...
- The Sloan-Kettering Institute for Cancer Research was awarded a $581,381 Project Grant by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The project aims to gain a better understanding of DNA damage repair pathways and how they go awry in cancer, with the goal of informing more effective therapeutic approaches. Specifically, the research will...
- This federal Project Grant award of $1,943,750.00, awarded on August 8, 2025, is provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The grant supports fundamental research and advanced training focused on understanding the molecular mechanisms that regulate the mitotic DNA damage response. The project, led by researchers at The Washington University, aims to 1) reveal how ubiquitinated histone H2A acts...
- This $516,608 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to understand the mechanisms and regulation of DNA recombination in budding and fission yeast. The key research focus areas are: 1) studying DNA end resection, the critical first step in homologous recombination, within heterochromatin regions, 2) investigating how lagging strand synthesis proceeds during...
- This federal Project Grant award of $617,007 was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to conduct research on the molecular mechanisms of DNA double-strand break repair through non-homologous end joining (NHEJ). The research aims to elucidate how DNA ends are held together and coordinated with end processing enzymes to maximize the fidelity of NHEJ and minimize genome alterations. The...
This Project Grant award of $524,815 was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Saint Louis University (SLU) on August 28, 2025. The grant supports research aimed at understanding the mechanisms of homologous recombination (HR), a DNA repair pathway critical for maintaining genomic stability. The key focus is on elucidating how mediator proteins and RAD51 paralogs facilitate the formation and stabilization of the RAD51 nucleoprotein filament, which is a critical pre-synaptic step in the HR process. The research seeks to decipher how the single-stranded DNA-double-stranded DNA junction is recognized through RPA-RAD52-RAD51 interactions, and the underlying mechanisms by which mediators and RAD51 paralogs promote and regulate the RAD51 filament formation. This work has significant implications for understanding and potentially targeting DNA repair processes relevant to cancer development and progression.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $13.5k | 9/12/25 | ||
| Not listed | $511.3k | 8/27/25 |